Angiomax Patent Dispute: On-Sale Bar Applies To Distribution Agreement

Hospira's generic does not infringe The Medicine Company's patented method of making Angiomax, US Federal Circuit finds, but leaves question of  whether TMC's distribution agreement covers manufacturing process for the district court to decide.

Court of Appeals for Federal Circuit Lafayette Park Across from White House Washington DC

The US Court of Appeals for the Federal Circuit concluded that The Medicines Co.'s agreement for the distribution of Angiomax (bivalirudin) was a commercial offer for sale, but it has left it for a district court to decide if the agreement covers the patent on TMC's improved manufacturing process.

In its Feb. 6 decison in The Medicines Company v. Hospira Inc. the court further clarifies the application...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet